Towards molecular characterization of sporadic epithelial ovarian carcinoma

Towards molecular characterization of sporadic epithelial ovarian carcinoma - ORCA (OvaRian CAncer research)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38084

Enrollment

600

Registered

2012-10-02

Start date

2012-12-19

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Women with an ovarian carcinoma, all histological subtypes and all stages and grades will be included. Approximately 300 new patients suspected of ovarian cancer are expected each year within the CGOA (AMC, AvL/NKI, VUmc), of whom 100 are expected to be diagnosed with a benign ovarian tumour, and 200 with a malignant ovarian tumour.

Exclusion criteria

Exclusion criteria: Women with an expected benign ovarian tumour.

Design outcomes

Primary

Measure	Time frame
By combining techniques and apllying them to the same large series of patients, we aim to fully describe the characteristics of ovarian carcinomas that determine whether or not a patient reponds well to her treatment. We hope to be able to discriminate subclasses of ovarian cancer that offer leads for novel therapeutic approaches. By using the infrastructure of the cooperation that has been set up between the various medical centers we will set up new pospective clinical trials for the treatment of ovarian cancer based on the protein and genetic information generated by our studies.	—

Measure

Time frame

By combining techniques and apllying them to the same large series of patients, we aim to fully describe the characteristics of ovarian carcinomas that determine whether or not a patient reponds well to her treatment. We hope to be able to discriminate subclasses of ovarian cancer that offer leads for novel therapeutic approaches. By using the infrastructure of the cooperation that has been set up between the various medical centers we will set up new pospective clinical trials for the treatment of ovarian cancer based on the protein and genetic information generated by our studies.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results